Centre for Amyloidosis and Acute Phase Proteins


National Amyloidosis Centre

Head, Centre for Amyloidosis & Acute Phase Proteins and NAC Research Lead

Professor Julian Gillmore020 7433 2811
NAC Clinical LeadDr Helen Lachmann020 7433 2811
Deputy Clinical and Research LeadDr Marianna Fontana020 7433 2764
Emeritus Professor and ConsultantProfessor Sir Mark Pepys020 7433 2801/2802
Professors/ConsultantsProfessor Philip Hawkins020 7433 2811
 Professor Ashutosh Wechalekar020 7433 2811
Readers/Senior Lecturers/ConsultantsDr Dan Knight020 7433 2765
 Dr Ayesha Shameem Mahmood020 7433 2778
 Dr Sajitha Sachchithanantham020 7433 2778
 Dr Carol Whelan020 7433 2789
Clinical Research StaffDr Ana Martinez De Azcona Naharro020 7433 2777
 Dr Faye Sharpley020 7433 2763
Lead NurseAngelique Smit020 7433 2770
Specialist/Research NursesBeth Clarkson-Dodd020 7433 2856
 Darren Foard020 7433 2814
 Svetla Strehina020 7433 2880
 Michael Wood020 7433 2797
Operations ManagerAdrian Machinn020 7433 2732
Outpatients Administrative ManagerRamon Lamarca020 7433 2756
Medical SecretariesSarah Louth / Cauvery Shelat / Kay Law020 7433 2811/2737/2798
Transport & AccommodationOnana Ayissi020 7433 2812
General Enquiries 020 7433 2725
Fax 020 7433 2817

The NHS National Amyloidosis Centre is the only centre in the UK specialising in amyloidosis and is part of University College London Centre for Amyloidosis and Acute Phase Proteins, one of the world's leading centres for amyloid research. The Centre has "state of the art" clinical and research facilities, and a team of highly qualified clinical, research and support staff.

We pioneered scintigraphic imaging (scanning) of amyloid as a quantitative diagnostic procedure and provide a comprehensive clinical service for patients with all types of acquired and hereditary systemic amyloidosis.  The NHS National Amyloidosis Centre is commissioned by NHS National Specialised Services and funded by the Department of Health to provide a diagnostic and management advice service for the UK's national caseload of patients with amyloidosis and related disorders. The clinical service includes:

    • Detailed clinical assessment.
    • Diagnosis, quantification and monitoring of amyloidosis with whole body SAP scintigraphy.
    • Comprehensive expert diagnostic and monitoring studies of the heart, as required, by cardiac magnetic resonance, echocardiography and DPD scanning.
    • Review of diagnostic biopsies and specialised immunohistochemistry to determine amyloid type.
    • Characterisation and exclusion of hereditary amyloidosis by DNA testing; genetic counselling.
    • Measurement and monitoring of specialised biochemical (blood) tests for serum free light chains and serum amyloid A protein.
    • Recommendations for treatment and monitoring response.
    • 3‑12 monthly follow‑up to assess response and further treatment requirements. Sometimes follow‑up assessment can be performed by telephone if patients live far away.
    • Providing information and support to amyloidosis patients, their families and health providers.
    • Systematic evaluation of existing and new treatments.
    • Diagnosis, monitoring and treatment of inherited fever syndromes.